(Reuters) - India's Lupin Ltd said it won U.S. approval for a generic version of Pfizer Inc's big-selling Lyrica nerve pain treatment.

A spokesman for Lupin said it has not yet launched its version of Lyrica, which is also known as pregabalin.

Lyrica tallied U.S. sales of about $1.8 billion for the year ended in March, Lupin said, citing data from IMS Health Inc.

(Reporting by Lewis Krauskopf; Editing by Gerald E. McCormick)